Abstract |
Toxicity-reduced conditioning is being used for allogeneic stem cell transplantation in older and/or comorbid patients. We report on the treatment of 133 patients (median age: 55.6 years [23-73 years]) with acute myeloid leukemia (AML)/ myelodysplastic syndrome (MDS; n = 81), myeloproliferative syndromes (MPS; n = 20), and lymphoid malignancies (n = 32) using conditioning with FBM: fludarabine (5 x 30 mg/m(2)), 1,3-bis(2-chloroethyl)-1-nitrosourea (or carmustine, BCNU; 2 x 200 mg/m(2)), and melphalan (140 mg/m(2)). Patients 55 years or older received fludarabine with reduced BCNU (2 x150 mg/m(2)) and melphalan (110 mg/m(2)). After engraftment, chimerism analyses revealed complete donor hematopoiesis in 95.7% of patients. With a median follow-up of 58.5 months, 3- and 5-year overall survival (OS) was 53.0% and 46.1%, event-free survival (EFS) was 46.4% and 41.9%. No significant differences in OS and EFS were evident considering disease status (early vs advanced), patient age (<55 vs> or =55 years), or donor type (related vs unrelated) in univariate and multivariate analyses. The cumulative 5-year incidence of death due to relapse was 20.1%. Nonrelapse mortality (NRM) after 100 days and 1 year was 15.8% and 26.3%. Among patients with AML/MDS, advanced cases (n = 64, including 61 with active disease) showed an OS of 44.6% and 42.4% after 3 and 5 years, respectively. Therefore, FBM conditioning combines effective disease control with low NRM.
|
Authors | Reinhard Marks, Karin Potthoff, Joachim Hahn, Gabriele Ihorst, Hartmut Bertz, Alexandros Spyridonidis, Ernst Holler, Jürgen M Finke |
Journal | Blood
(Blood)
Vol. 112
Issue 2
Pg. 415-25
(Jul 15 2008)
ISSN: 1528-0020 [Electronic] United States |
PMID | 18451310
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)
|
Chemical References |
- Vidarabine
- fludarabine
- Melphalan
- Carmustine
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use, toxicity)
- Carmustine
(administration & dosage)
- Female
- Hematologic Neoplasms
(mortality, therapy)
- Hematopoietic Stem Cell Transplantation
(methods, mortality)
- Humans
- Male
- Melphalan
(administration & dosage)
- Middle Aged
- Survival Analysis
- Transplantation Conditioning
(methods)
- Transplantation, Homologous
- Vidarabine
(administration & dosage, analogs & derivatives)
|